Atomo Diagnostics Ltd

Atomo Diagnostics has a current ratio of 3.03, indicating strong short-term liquidity, but its operating cash flow of -1.96 million AUD and free cash flow of -3.42 million AUD suggest ongoing cash burn. The company's debt-to-equity ratio is 0.03, reflecting a conservative capital structure with minimal leverage. However, the negative return on equity of -71.26% and return on assets of -53.58% highlight significant underperformance relative to its equity and asset base. The company's profitability is challenged, with a net loss of 4.97 million AUD and an operating loss of 4.95 million AUD in the latest period. These figures fall well below the industry median for operating margins and net margins, which are typically positive for firms in the Advanced Medical Equipment & Technology sector. The gross profit of 1.92 million AUD is modest given the company's revenue of 3.79 million AUD, indicating low gross margin efficiency. Atomo Diagnostics' revenue is concentrated in a few key products, including the Atomo HIV Self-Test and AtomoRapid Pascal platform, with no disclosed geographic diversification in the input data. The company has supply agreements in place for infectious disease testing applications, but the lack of segment or geographic breakdown limits visibility into potential concentration risks. The company's growth trajectory is uncertain, with no specific revenue growth or decline percentages provided in the input data. However, the negative operating and net income suggest a lack of profitability, which could hinder long-term growth unless significant cost reductions or revenue increases are achieved. The company's outlook for the current and next fiscal years is not quantified in the input data, but the ongoing losses indicate a need for strategic adjustments. The risk assessment highlights medium liquidity risk due to negative operating and free cash flows, despite a strong current ratio. The dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. The company's capital expenditures are minimal at -33,890 AUD, suggesting a focus on cost control rather than expansion. Recent events include the commercialization of products across international markets and the establishment of supply agreements for testing applications targeting infectious diseases. No recent filings or transcripts are provided in the input data to further detail these developments.